Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheon
Biotech
Alzheon's Alzheimer's asset axes brain injury biomarker in trial
Alzheon linked the oral beta amyloid blocker to a reduction in a marker of neuronal stress and brain injury in one-year data from its phase 2 study.
Nick Paul Taylor
Sep 20, 2022 6:55am
Pfizer taps former CVS exec Denton for CFO role—Chutes & Ladders
Apr 15, 2022 9:30am
'Big hole' no more as Aduhelm opens AD drug funding 'floodgates'
Jun 10, 2021 11:03am
No IPO? No problem: Alzheon bags $47M for Alzheimer's trial
Aug 20, 2020 12:01am
It's a case of déjà vu as Alzheon pulls IPO again
Jan 17, 2019 9:55am
Second time lucky? Alzheon tries for smaller IPO
Aug 28, 2018 9:15am
